These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 17991316)

  • 1. [Expression and significance of GLUT-1 and DNA-PKcs in serous ovarian tumors].
    Cai Y; Shao SL; Wang QH; Yan LJ; Wang XY; Wang LX
    Ai Zheng; 2007 Nov; 26(11):1188-93. PubMed ID: 17991316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Expression of GLUT-1, p63 and DNA-Pkcs in serous ovarian tumors and their significance].
    Shao SL; Cai Y; Wang QH; Yan LJ; Zhao XY; Wang LX
    Zhonghua Zhong Liu Za Zhi; 2007 Sep; 29(9):697-700. PubMed ID: 18246802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of glucose transporter protein 1 and p63 in serous ovarian tumor.
    Cai Y; Zhai JJ; Feng BB; Duan XZ; He XJ
    J Obstet Gynaecol Res; 2014 Jul; 40(7):1925-30. PubMed ID: 25056472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Correlation of hK6 expression with clinicopathological features and prognosis in epithelial ovarian cancer].
    Hu CJ; Zhang F; Chen YJ; Sun XM; Zheng JF
    Zhonghua Zhong Liu Za Zhi; 2009 Jul; 31(7):520-3. PubMed ID: 19950700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathological significance of DEK overexpression in serous ovarian tumors.
    Han S; Xuan Y; Liu S; Zhang M; Jin D; Jin R; Lin Z
    Pathol Int; 2009 Jul; 59(7):443-7. PubMed ID: 19563407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Expressions of Cx43 and Skp2 in epithelial ovarian tumor and their clinical significances].
    Hu YQ; Liu YJ
    Ai Zheng; 2005 Jan; 24(1):104-9. PubMed ID: 15642212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Expression and clinical relevance of ARHI, STAT3 and E2F1 in ovarian serous carcinoma].
    Zhang J; Li YH; Cui AR; Wang JL; Cheng JX; Wang SJ
    Zhonghua Zhong Liu Za Zhi; 2008 Dec; 30(12):905-9. PubMed ID: 19173990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypoxic status in ovarian serous and mucinous tumors: relationship between histological characteristics and HIF-1alpha/GLUT-1 expression.
    Iida T; Yasuda M; Miyazawa M; Fujita M; Osamura RY; Hirasawa T; Muramatsu T; Murakami M; Saito K; Mikami M
    Arch Gynecol Obstet; 2008 Jun; 277(6):539-46. PubMed ID: 18026974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with high mitotic activity and high FIGO stage.
    Brustmann H; Naudé S
    Gynecol Oncol; 2002 Jan; 84(1):47-52. PubMed ID: 11748975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of GLUT-1 glucose transporter in borderline and malignant epithelial tumors of the ovary.
    Cantuaria G; Magalhaes A; Penalver M; Angioli R; Braunschweiger P; Gomez-Marin O; Kanhoush R; Gomez-Fernandez C; Nadji M
    Gynecol Oncol; 2000 Oct; 79(1):33-7. PubMed ID: 11006027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Expression of SATB1 and BRMS1 in ovarian serous adenocarcinoma and its relationship with clinieopathological features].
    Zhao XL; Wang P
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2011 Jan; 42(1):82-5, 105. PubMed ID: 21355308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Expression and promotor methylation of p73 gene in ovarian epithelial tumors].
    Zhang YL; Guo XR; Shen DH; Cheng YX; Liang XD; Chen YX; Wang Y
    Zhonghua Bing Li Xue Za Zhi; 2012 Jan; 41(1):33-8. PubMed ID: 22455848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Expression of glucose transporter-1 and its correlation with basic fibroblast growth factor and proliferating cell nuclear antigen in epithelial ovarian neoplasm].
    Zhao SJ; Liu JY; Ren FR; Feng YJ
    Zhonghua Fu Chan Ke Za Zhi; 2005 Apr; 40(4):264-8. PubMed ID: 15924676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Expression of KiSS-1, matrix metalloproteinase-9, nuclear factor-kappaBp65 in ovarian tumour].
    Gao GL; Liu LD; Zou XS; Chen WX
    Zhonghua Fu Chan Ke Za Zhi; 2007 Jan; 42(1):34-8. PubMed ID: 17331419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA fragmentation factor (DFF45): expression and prognostic value in serous ovarian cancer.
    Brustmann H
    Pathol Res Pract; 2006; 202(10):713-20. PubMed ID: 16962250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High expression of tissue inhibitor of metalloproteinase-2 in serous ovarian carcinomas and the role of this expression in ovarian tumorigenesis.
    Kim TJ; Rho SB; Choi YL; Choi CH; Lee JW; Bae DS; Ahn G; Lee JH; Kim BG
    Hum Pathol; 2006 Jul; 37(7):906-13. PubMed ID: 16784992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanog is highly expressed in ovarian serous cystadenocarcinoma and correlated with clinical stage and pathological grade.
    Pan Y; Jiao J; Zhou C; Cheng Q; Hu Y; Chen H
    Pathobiology; 2010; 77(6):283-8. PubMed ID: 21266826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Expression of THY1 gene in epithelial ovarian cancer].
    Zeng LQ; Peng ZL; Duan ZL
    Zhonghua Zhong Liu Za Zhi; 2009 Feb; 31(2):118-20. PubMed ID: 19538887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progressive loss of selenium-binding protein 1 expression correlates with increasing epithelial proliferation and papillary complexity in ovarian serous borderline tumor and low-grade serous carcinoma.
    Zhang C; Wang YE; Zhang P; Liu F; Sung CJ; Steinhoff MM; Quddus MR; Lawrence WD
    Hum Pathol; 2010 Feb; 41(2):255-61. PubMed ID: 19896693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.